Gene therapy for the treatment of chronic peripheral nervous system pain

Neurobiology of Disease

Volumn 48, Issue 2, 2012, Pages 255-270

  Goins, William F ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Adenovirus; Animal models; Endorphin; Enkephalin; Gene therapy; Glutamic acid decarboxylase; Herpes simplex virus; Interleukins; Lentivirus; Neuropathic pain; Neurotransmitters; Neurotrophins; Nociceptive pain; Peripheral nervous system; Plasmid DNA; Retrovirus; Spinal cord; Viral vectors

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; CARBAMAZEPINE; CORTICOSTEROID; ENKEPHALIN; GABAPENTIN; GROWTH FACTOR; HERPES SIMPLEX VIRUS VECTOR; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; INTERLEUKIN 10; LENTIVIRUS VECTOR; LEUCINE ENKEPHALIN; NAPROXEN; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; OPIATE; OPIATE PEPTIDE; PARACETAMOL; PARVOVIRUS VECTOR; PLASMID VECTOR; PREGABALIN; PREPROENKEPHALIN; RETROVIRUS VECTOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANALGESIA; ANTISENSE THERAPY; BONE METASTASIS; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; GENE; GENE EXPRESSION; GENE THERAPY; GROWTH FACTOR GENE THERAPY; HUMAN; HUMAN PRE PROENKEPHALIN GENE; HYPERALGESIA; INFLAMMATORY PAIN; INTRACTABLE PAIN; MORBIDITY; NERVE INJURY; NEUROPATHIC PAIN; NEUROTRANSMITTER BASED GENE THERAPY; NEUROTROPHIC FACTOR GENE THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPIOID PEPTIDE GENE GENE THERAPY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TRANSGENE; TREATMENT RESPONSE; TRPV1 MODULATOR GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; CHRONIC PAIN; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PAIN MANAGEMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; VIRUSES;

EID: 84865559721     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.05.005     Document Type: Review

References (174)

1. Alba R., et al. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005, 12(Suppl. 1):S18-S27.
2. An K., et al. Subarachnoid transplantation of immortalized galanin-overexpressing astrocytes attenuates chronic neuropathic pain. Eur. J. Pain 2010, 14:595-601.
3. Antunes Bras J.M., et al. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J. Neurochem. 1998, 70:1299-1303.
4. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 1984, 7:309-338.
5. Beard B.C., et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum. Gene Ther. 2007, 18:423-434.
6. Belyanskaya L., et al. Effects of carbon nanotubes on primary neurons and glial cells. Neurotoxicology 2009, 30:702-711.
7. Bennett M.I., et al. Methodological quality in randomised controlled trials of transcutaneous electric nerve stimulation for pain: low fidelity may explain negative findings. Pain 2011, 152:1226-1232.
8. Beutler A.S., et al. Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts. J. Neurochem. 1995, 64:475-481.
9. Beutler A.S., et al. Intrathecal gene transfer by adeno-associated virus for pain. Curr. Opin. Mol. Ther. 2005, 7:431-439.
10. Braz J., et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J. Neurosci. 2001, 21:7881-7888.
11. Chadeuf G., et al. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2000, 2:260-268.
12. Chattopadhyay M., et al. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 2005, 12:1377-1384.
13. Chattopadhyay M., et al. Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol. Ther. 2005, 12:307-313.
14. Chattopadhyay M., et al. Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 2009, 132:879-888.
15. V1.7 in DRG neurons. Eur. J. Pain 2011, 15:913-920.
16. Chattopadhyay M., et al. Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol. Pain 2012, 8:17.
17. Chen S.L., et al. dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20096-20101.
18. Chen K.H., et al. Intrathecal coelectrotransfer of a tetracycline-inducible, three-plasmid-based system to achieve tightly regulated antinociceptive gene therapy for mononeuropathic rats. J. Gene Med. 2008, 10:208-216.
19. Chou R., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 2009, 10:113-130.
20. Chuang Y.C., et al. Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. J. Urol. 2003, 170:2044-2048.
21. Chuang Y.C., et al. Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. Urology 2005, 65:804-810.
22. Clement N., et al. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum. Gene Ther. 2009, 20:796-806.
23. Conway J.E., et al. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 1997, 71:8780-8789.
24. Croyle M.A., et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 2002, 13:1887-1900.
25. Davidson B.L., Breakefield X.O. Viral vectors for gene delivery to the nervous system. Nat. Rev. Neurosci. 2003, 4:353-364.
26. Derse D., et al. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J. Virol. 2007, 81:6731-6741.
27. Donsante A., et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
28. Dubinsky R.M., Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74:173-176.
29. Eaton M.J., et al. Lumbar transplants of immortalized serotonergic neurons alleviate chronic neuropathic pain. Pain 1997, 72:59-69.
30. Eaton M.J., et al. Transplants of neuronal cells bioengineered to synthesize GABA alleviate chronic neuropathic pain. Cell Transplant. 1999, 8:87-101.
31. Eaton M.J., et al. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther. 2002, 9:1387-1395.
32. Epstein A.L. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 2009, 16:709-715.
33. Finegold A.A., et al. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum. Gene Ther. 1999, 10:1251-1257.
34. Finegold A.A., et al. In vivo control of NMDA receptor transcript level in motoneurons by viral transduction of a short antisense gene. Brain Res. Mol. Brain Res. 2001, 90:17-25.
35. Fink D.J., et al. Gene therapy for pain: results of a phase I clinical trial. Ann. Neurol. 2011, 70:207-212.
36. Fishbain D.A., et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008, 9:444-459.
37. Fleming J., et al. Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. Hum. Gene Ther. 2001, 12:77-86.
38. Fossat P., et al. Knockdown of L calcium channel subtypes: differential effects in neuropathic pain. J. Neurosci. 2010, 30:1073-1085.
39. Garraway S.M., et al. siRNA-mediated knockdown of the NR1 subunit gene of the NMDA receptor attenuates formalin-induced pain behaviors in adult rats. J. Pain 2009, 10:380-390.
40. Garry E.M., et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain 2005, 118:97-111.
41. Girard C., et al. Grafts of brain-derived neurotrophic factor and neurotrophin 3-transduced primate Schwann cells lead to functional recovery of the demyelinated mouse spinal cord. J. Neurosci. 2005, 25:7924-7933.
42. Glatzel M., et al. Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:442-447.
43. L flanking repeats. J. Virol. 1994, 68:2239-2252.
44. Goins W.F., et al. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J. Virol. 1999, 73:519-532.
45. Gold M.S., et al. Co-expression of nociceptor properties in dorsal root ganglion neurons from the adult rat in vitro. Neuroscience 1996, 71:265-275.
46. Gonzalez S.C., et al. Readministration of adenoviral gene delivery to dopamine neurons. Neuroreport 2007, 18:1609-1614.
47. Goss J.R., et al. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther. 2001, 8:551-556.
48. Goss J.R., et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann. Neurol. 2002, 52:662-665.
49. Goss J.R., et al. HSV delivery of a ligand-regulated endogenous ion channel gene to sensory neurons results in pain control following channel activation. Mol. Ther. 2011, 19:500-506.
50. Gu Y., et al. Remote nerve injection of mu opioid receptor adeno-associated viral vector increases antinociception of intrathecal morphine. J. Pain 2005, 6:447-454.
51. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
52. Halbert C.L., et al. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 2000, 74:1524-1532.
53. Hamilton M.M., et al. Repeated administration of adenovector in the eye results in efficient gene delivery. Invest. Ophthalmol. Vis. Sci. 2006, 47:299-305.
54. Hao S., et al. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain 2003, 102:135-142.
55. Hao S., et al. HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol. Ther. 2003, 8:367-375.
56. Hao S., et al. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol. Pain 2006, 2:6.
57. Hao S., et al. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007, 14:1010-1016.
58. Hao S., et al. Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain. Behav. Brain. Res. 2009, 197:84-89.
59. Hao S., et al. Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur. J. Pain 2009, 13:380-386.
60. Hasnie F.S., et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 2007, 144:1495-1508.
61. Hino M., et al. Intrathecal transplantation of autologous macrophages genetically modified to secrete proenkephalin ameliorated hyperalgesia and allodynia following peripheral nerve injury in rats. Neurosci. Res. 2009, 64:56-62.
62. Hootman J.M., Helmick C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006, 54:226-229.
63. Jia H.B., et al. Effects of recombinant human erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B. Can. J. Anaesth. 2009, 56:597-603.
64. Jones T.L., et al. Afferent fiber-selective shift in opiate potency following targeted opioid receptor knockdown. Pain 2003, 106:365-371.
65. Jones T.L., et al. GABAB receptors on central terminals of C-afferents mediate intersegmental Adelta-afferent evoked hypoalgesia. Eur. J. Pain 2005, 9:233-242.
66. Julius D., Basbaum A.I. Molecular mechanisms of nociception. Nature 2001, 413:203-210.
67. Kao J.H., et al. Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm. J. Pharmacol. Exp. Ther. 2010, 334:739-745.
68. Kim J., et al. Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2. Biochem. Biophys. Res. Commun. 2009, 388:73-78.
69. Kim S.J., et al. Effective relief of neuropathic pain by adeno-associated virus-mediated expression of a small hairpin RNA against GTP cyclohydrolase 1. Mol. Pain 2009, 5:67.
70. Kim Y.M., et al. Reduction of allodynia by intrathecal transplantation of microencapsulated porcine chromaffin cells. Artif. Organs. 2009, 33:240-249.
71. Krisky D.M., et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 1998, 5:1593-1603.
72. Kuraishi Y., et al. Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci. 2004, 74:2619-2626.
73. Kuzmin A.I., et al. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors. Mol. Ther. 2001, 3:293-301.
74. Lan L.S., et al. Down-regulation of toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. Mol. Pain 2010, 6:2.
75. Ledeboer A., et al. Spinal cord glia and interleukin-1 do not appear to mediate persistent allodynia induced by intramuscular acidic saline in rats. J. Pain 2006, 7:757-767.
76. Ledeboer A., et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. 2007, 21:686-698.
77. Ledley F.D. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 1995, 6:1129-1144.
78. Lee T.H., et al. In vivo electroporation of proopiomelanocortin induces analgesia in a formalin-injection pain model in rats. Pain 2003, 104:159-167.
79. Lee I.O., et al. NMDA-R1 antisense oligodeoxynucleotides modify formalin-induced nociception and spinal c-Fos expression in rat spinal cord. Pharmacol. Biochem. Behav. 2004, 79:183-188.
80. Lee B., et al. Constitutive GABA expression via a recombinant adeno-associated virus consistently attenuates neuropathic pain. Biochem. Biophys. Res. Commun. 2007, 357:971-976.
81. Li J., et al. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum. Gene Ther. 2008, 19:958-964.
82. Li W., et al. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. Mol. Vis. 2009, 15:267-275.
83. Lin C.R., et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther. 2002, 9:1247-1253.
84. Lin C.R., et al. Sonoporation-mediated gene transfer into adult rat dorsal root ganglion cells. J. Biomed. Sci. 2010, 17:44.
85. Lindner M.D., et al. Analgesic effects of adrenal chromaffin allografts: contingent on special procedures or due to experimenter bias?. J. Pain 2003, 4:64-73.
86. Ling W., et al. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev. 2011, 30:300-305.
87. Lipshutz G.S., et al. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. Mol. Ther. 2000, 2:374-380.
88. Liu J., et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol. Ther. 2004, 10:57-66.
89. Liu W., et al. A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury. Neurosci. Lett. 2008, 432:13-18.
90. Lock M., et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene Ther. 2010, 21:1259-1271.
91. Lotze M.T., Kost T.A. Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther. 2002, 9:692-699.
92. Lu C.Y., et al. Gene-gun particle with pro-opiomelanocortin cDNA produces analgesia against formalin-induced pain in rats. Gene Ther. 2002, 9:1008-1014.
93. Lu Y., et al. Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol. Ther. 2007, 15:1812-1819.
94. Lu Y., et al. Joint capsule treatment with enkephalin-encoding HSV-1 recombinant vector reduces inflammatory damage and behavioural sequelae in rat CFA monoarthritis. Eur. J. Neurosci. 2008, 27:1153-1165.
95. Lynagh T., Lynch J.W. An improved ivermectin-activated chloride channel receptor for inhibiting electrical activity in defined neuronal populations. J. Biol. Chem. 2010, 285:14890-14897.
96. Machelska H., et al. Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain. Mol. Pain 2009, 5:72.
97. Maeda S., et al. Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats. Mol. Pain 2008, 4:65.
98. Mannes A.J., et al. Adenoviral gene transfer to spinal-cord neurons: intrathecal vs. intraparenchymal administration. Brain Res. 1998, 793:1-6.
99. Manning W.C., et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 1998, 9:477-485.
100. Martin B.I., et al. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006. Spine (Phila Pa 1976) 2009, 34:2077-2084.
101. Mazarakis N.D., et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 2001, 10:2109-2121.
102. Mellerick D.M., Fraser N. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology 1987, 158:265-275.
103. Meunier A., et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol. Ther. 2005, 4:608-616.
104. Meunier A., et al. Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol. Ther. 2007, 15:687-697.
105. Meunier A., et al. Lentiviral-mediated targeted transgene expression in dorsal spinal cord glia: tool for the study of glial cell implication in mechanisms underlying chronic pain development. J. Neurosci. Methods 2008, 167:148-159.
106. Milligan E.D., et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur. J. Neurosci. 2005, 21:2136-2148.
107. Milligan E.D., et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol. Pain 2005, 1:9.
108. Milligan E.D., et al. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 2006, 126:294-308.
109. Milligan E.D., et al. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol. 2006, 2:293-308.
110. Miyazato M., et al. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther. 2009, 16:660-668.
111. Miyazato M., et al. Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats. J. Urol. 2010, 184:1204-1210.
112. Moalem G., Tracey D.J. Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 2006, 51:240-264.
113. Naldini L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
114. Odom G.L., et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 2008, 16:1539-1545.
115. Oliveira H., et al. Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c. J. Control Release 2010, 143:350-358.
116. Omura S. Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents 2008, 31:91-98.
117. Palmer J.A., et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J. Virol. 2000, 74:5604-5618.
118. Patte-Mensah C., et al. Selective regulation of 3 alpha-hydroxysteroid oxido-reductase expression in dorsal root ganglion neurons: a possible mechanism to cope with peripheral nerve injury-induced chronic pain. Pain 2010, 150:522-534.
119. Peng X.M., et al. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol. 2006, 59:843-851.
120. Perez M.C., et al. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Ther. 2004, 11:1023-1032.
121. Pezet S., et al. Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol. Ther. 2006, 13:1101-1109.
122. Pinto M., et al. Opioids modulate pain facilitation from the dorsal reticular nucleus. Mol. Cell. Neurosci. 2008, 39:508-518.
123. Puskovic V., et al. Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol. Ther. 2004, 10:67-75.
124. Riviere C., et al. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther. 2006, 13:1300-1308.
125. Romero M.I., et al. Functional regeneration of chronically injured sensory afferents into adult spinal cord after neurotrophin gene therapy. J. Neurosci. 2001, 21:8408-8416.
126. Ryan D.A., Federoff H.J. Immune responses to herpes viral vectors. Hum. Gene Ther. 2009, 20:434-441.
127. Scholz J., Woolf C.J. Can we conquer pain?. Nat. Neurosci. 2002, 5:1062-1067. (Suppl.).
128. Shi L., et al. Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther. 2003, 10:1179-1188.
129. Sloane E., et al. Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain. Gene Ther. 2009, 16:1210-1222.
130. Soderquist R.G., et al. Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm. Res. 2010, 27:841-854.
131. Sol J.C., et al. Intrathecal grafting of porcine chromaffin cells reduces formalin-evoked c-Fos expression in the rat spinal cord. Cell Transplant. 2005, 14:353-365.
132. Song Z., et al. Gene knockdown with lentiviral vector-mediated intrathecal RNA interference of protein kinase C gamma reverses chronic morphine tolerance in rats. J. Gene Med. 2010, 12:873-880.
133. Srinivasan R., et al. An HSV vector system for selection of ligand-gated ion channel modulators. Nat. Methods 2007, 4:733-739.
134. Srinivasan R., et al. Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur. J. Neurosci. 2008, 28:1241-1254.
135. Stevens J.G. Human herpesviruses: a consideration of the latent state. Microbiol. Rev. 1989, 53:318-332.
136. Storek B., et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1055-1060.
137. Sun J., et al. Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats. Gene Ther. 2012, 19:101-108.
138. Takasaki I., et al. Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. J. Pharmacol. Exp. Ther. 2001, 296:270-275.
139. Tan P.H., et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 2005, 12:59-66.
140. Tan P.H., et al. Gene knockdown of the N-methyl-d-aspartate receptor NR1 subunit with subcutaneous small interfering RNA reduces inflammation-induced nociception in rats. Anesthesiology 2010, 112:1482-1493.
141. Toblin R.L., et al. A population-based survey of chronic pain and its treatment with prescription drugs. Pain 2011, 152:1249-1255.
142. Towne C., et al. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol. Pain 2009, 5:52.
143. Tsuchihara T., et al. Nonviral retrograde gene transfer of human hepatocyte growth factor improves neuropathic pain-related phenomena in rats. Mol. Ther. 2009, 17:42-50.
144. Tzabazis A.Z., et al. Antihyperalgesic effect of a recombinant herpes virus encoding antisense for calcitonin gene-related peptide. Anesthesiology 2007, 106:1196-1203.
145. Urabe M., et al. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 2002, 13:1935-1943.
146. Varnavski A.N., et al. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005, 12:427-436.
147. Vit J.P., et al. Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia. Mol. Pain 2009, 5:42.
148. Vulchanova L., et al. Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol. Pain 2010, 6:31.
149. Wang R., et al. Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain. Neuroscience 2003, 121:815-824.
150. Wang X., et al. Gene transfer to dorsal root ganglia by intrathecal injection: effects on regeneration of peripheral nerves. Mol. Ther. 2005, 12:314-320.
151. Watanabe T.S., et al. Adenoviral gene transfer in the peripheral nervous system. J. Orthop. Sci. 2006, 11:64-69.
152. Wilson S.P., et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3211-3216.
153. Wolfe D., et al. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 2007, 133:29-38.
154. Wolfe D., et al. A herpes simplex virus vector system for expression of complex cellular cDNA libraries. J. Virol. 2010, 84:7360-7368.
155. Wong L.F., et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 2004, 9:101-111.
156. Woolf C.J. Windup and central sensitization are not equivalent. Pain 1996, 66:105-108.
157. Wu C.M., et al. Regulated, electroporation-mediated delivery of pro-opiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats. Gene Ther. 2004, 11:933-940.
158. Yamashita M., et al. Transfection of rat cells with proopiomeranocortin gene, precursor of endogenous endorphin, using radial shock waves suppresses inflammatory pain. Spine (Phila Pa 1976) 2009, 34:2270-2277.
159. Yang Y., et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 1995, 69:2004-2015.
160. Yang H., et al. Enkephalin-encoding herpes simplex virus-1 decreases inflammation and hotplate sensitivity in a chronic pancreatitis model. Mol. Pain 2008, 4:8.
161. Yao M.Z., et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 2002, 112:409-416.
162. Yao M.Z., et al. Interleukin-2 gene has superior antinociceptive effects when delivered intrathecally. Neuroreport 2002, 13:791-794.
163. Yao M.Z., et al. Adenovirus-mediated interleukin-2 gene therapy of nociception. Gene Ther. 2003, 10:1392-1399.
164. Yeomans D.C., et al. Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpes virus that encodes human preproenkephalin. Mol. Ther. 2004, 9:24-29.
165. v1.7 sodium channels in primary afferents. Hum Gene Ther 2005, 16:271-277.
166. Yeomans D.C., et al. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol. Ther. 2006, 13:589-597.
167. Yokoyama H., et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum. Gene Ther. 2009, 20:63-71.
168. Yoshimura N., et al. Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology 2001, 57:116.
169. Younger J.W., et al. Prescription opioid analgesics rapidly change the human brain. Pain 2011, 152:1803-1810.
170. Zaiss A.K., Muruve D.A. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 2005, 5:323-331.
171. Zeng J., et al. Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons. Biomaterials 2007, 28:1443-1451.
172. Zhang G., et al. Enhanced peripheral analgesia using virally mediated gene transfer of the mu-opioid receptor in mice. Anesthesiology 2008, 108:305-313.
173. Zhou Z., et al. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther. 2008, 15:183-190.
174. Zou W., et al. Intrathecal herpes simplex virus type 1 amplicon vector-mediated human proenkephalin reduces chronic constriction injury-induced neuropathic pain in rats. Mol. Med. Report 2011, 4:529-533.